ACXP
- Acurx Pharmaceuticals, Inc.
()
Overview
Company Summary
Acurx Pharmaceuticals, Inc. (ACXP) is a pharmaceutical company that specializes in the development and commercialization of novel antibiotics to combat serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria.
ACXP focuses on developing innovative antibiotics that can offer effective treatment options for patients with limited therapeutic choices due to antibiotic resistance. The company's primary therapeutic focus is on infections in the gastrointestinal (GI) tract, which are often associated with issues like hospital-acquired and community-acquired bacterial infections.
Acurx Pharmaceuticals recognizes the pressing need for new antibiotics as traditional treatments become less effective against certain strains of bacteria. The company's approach involves leveraging its expertise in antibiotic drug development to create proprietary formulations that target MDR bacteria responsible for GI infections.
ACXP's pipeline includes a lead product candidate called ibezapolstat, which is an orally administered antibiotic that specifically targets Clostridium difficile infections (CDI). CDI is a bacterial infection commonly associated with the overuse of antibiotics and is prevalent in healthcare settings.
The company aims to develop ibezapolstat as a potentially valuable treatment option for patients suffering from CDI, delivering improved efficacy, safety, and convenience compared to existing therapies. ACXP's focus on the GI tract reinforces its commitment to addressing unmet medical needs in this specific area.
Overall, Acurx Pharmaceuticals is dedicated to harnessing scientific advancements and innovation to develop antibiotics that can combat antibiotic resistance and improve patient outcomes in the treatment of life-threatening infections.